The Impact of Race on Survival and Treatment in Veterans Treated for Metastatic Castration-Resistant Prostate Cancer.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
355 patients met eligibility criteria.
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
[CONCLUSIONS] Black veterans with prostate cancer treated with ARPIs lived approximately 6 months longer after developing mCRPC but had a shorter lifespan-by about 3 years-compared with White patients. Differences in tumor biology may help explain why Black individuals develop prostate cancer at a younger age and exhibit better responses to cancer therapy.
[BACKGROUND] Black individuals have higher incidence and mortality rates of prostate cancer than White individuals, and existing literature on treatment sequencing strategies in metastatic castration-
- p-value P<.001
- p-value P<.0001
- 95% CI 35-38
- 연구 설계 cohort study
APA
Candelieri-Surette D, Cheranda N, et al. (2025). The Impact of Race on Survival and Treatment in Veterans Treated for Metastatic Castration-Resistant Prostate Cancer.. Journal of the National Comprehensive Cancer Network : JNCCN, 23(12), 507-515. https://doi.org/10.6004/jnccn.2025.7078
MLA
Candelieri-Surette D, et al.. "The Impact of Race on Survival and Treatment in Veterans Treated for Metastatic Castration-Resistant Prostate Cancer.." Journal of the National Comprehensive Cancer Network : JNCCN, vol. 23, no. 12, 2025, pp. 507-515.
PMID
41671453 ↗
Abstract 한글 요약
[BACKGROUND] Black individuals have higher incidence and mortality rates of prostate cancer than White individuals, and existing literature on treatment sequencing strategies in metastatic castration-resistant prostate cancer (mCRPC) is limited and conflicting. Understanding the interplay between race and treatment could optimize care and improve overall survival (OS).
[METHODS] This retrospective observational cohort study assessed survival outcomes based on race and initial androgen receptor pathway inhibitor (ARPI) treatment among veterans with mCRPC. Participants included White or Black veterans diagnosed with mCRPC between January 1, 2011, and March 12, 2024, initially treated with either abiraterone or enzalutamide. The primary outcome was OS measured from the date of diagnosis and from the start of initial therapy. Kaplan-Meier estimates and Cox proportional hazards models were used to evaluate outcome differences by race and treatment.
[RESULTS] A total of 12,355 patients met eligibility criteria. The mean age of the cohort was 74.57 years, with Black patients diagnosed approximately 4 years younger than White patients (71.77 vs 75.60, respectively; P<.001). Median prostate-specific antigen and mean Charlson comorbidity index scores were higher among Black patients. Median OS was higher in Black patients compared with White patients (36.3 months [95% CI, 35-38] vs 31 months [95% CI, 30.3-31.7], respectively; inverse probability of treatment weighting hazard ratio [IPTW HR], 0.80; P<.0001) Median OS was also longer among patients prescribed enzalutamide compared with those prescribed abiraterone (28 months [95% CI, 27.0-28.9] vs 23.7 months [95% CI, 23.1-24.2], respectively; IPTW HR, 1.14; P<.0001). No significant race-by-treatment interaction was observed.
[CONCLUSIONS] Black veterans with prostate cancer treated with ARPIs lived approximately 6 months longer after developing mCRPC but had a shorter lifespan-by about 3 years-compared with White patients. Differences in tumor biology may help explain why Black individuals develop prostate cancer at a younger age and exhibit better responses to cancer therapy.
[METHODS] This retrospective observational cohort study assessed survival outcomes based on race and initial androgen receptor pathway inhibitor (ARPI) treatment among veterans with mCRPC. Participants included White or Black veterans diagnosed with mCRPC between January 1, 2011, and March 12, 2024, initially treated with either abiraterone or enzalutamide. The primary outcome was OS measured from the date of diagnosis and from the start of initial therapy. Kaplan-Meier estimates and Cox proportional hazards models were used to evaluate outcome differences by race and treatment.
[RESULTS] A total of 12,355 patients met eligibility criteria. The mean age of the cohort was 74.57 years, with Black patients diagnosed approximately 4 years younger than White patients (71.77 vs 75.60, respectively; P<.001). Median prostate-specific antigen and mean Charlson comorbidity index scores were higher among Black patients. Median OS was higher in Black patients compared with White patients (36.3 months [95% CI, 35-38] vs 31 months [95% CI, 30.3-31.7], respectively; inverse probability of treatment weighting hazard ratio [IPTW HR], 0.80; P<.0001) Median OS was also longer among patients prescribed enzalutamide compared with those prescribed abiraterone (28 months [95% CI, 27.0-28.9] vs 23.7 months [95% CI, 23.1-24.2], respectively; IPTW HR, 1.14; P<.0001). No significant race-by-treatment interaction was observed.
[CONCLUSIONS] Black veterans with prostate cancer treated with ARPIs lived approximately 6 months longer after developing mCRPC but had a shorter lifespan-by about 3 years-compared with White patients. Differences in tumor biology may help explain why Black individuals develop prostate cancer at a younger age and exhibit better responses to cancer therapy.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.